Phathom Pharmaceuticals, Inc. Contracts & Agreements

Letter Agreement to Vonoprazan Commercial Supply Agreement, dated September 4, 2024, by and among Evonik Operations GmbH and the Registrant (Filed With SEC on November 7, 2024)

Underwriting Agreement, dated August 19, 2024, by and among Phathom Pharmaceuticals, Inc. and Evercore Group L.L.C., Stifel, Nicolaus & Company, Incorporated and Guggenheim... (Filed With SEC on August 19, 2024)

Form of Pre-Funded Warrant (Filed With SEC on August 19, 2024)

Amended and Restated Non-Employee Director Compensation Program (Filed With SEC on August 8, 2024)

Description of Registered Securities (Filed With SEC on March 7, 2024)

First Amendment to the Commercial Supply Agreement, dated as of December 6, 2023, by and among Catalent Pharma Solutions, LLC and the Registrant (Filed With SEC on March 7, 2024)

Fourth Amendment to the Loan and Security Agreement, dated December 14, 2023, by and among Hercules Capital and the Registrant (Filed With SEC on March 7, 2024)

Phathom Pharmaceuticals Inc. 2024 Bonus Plan (Filed With SEC on March 7, 2024)

First Amendment to Vonoprazan Commercial Supply Agreement (Filed With SEC on August 10, 2023)

Amendment and Restated Non-Employee Director Compensation Program (Filed With SEC on August 10, 2023)

Underwriting Agreement, dated May 23, 2023, by and among Phathom Pharmaceuticals, Inc. and Jefferies LLC and Evercore Group L.L.C., as representatives of the several underwriters... (Filed With SEC on May 24, 2023)

Commercial Supply Agreement with Evonik Operations GmbH entered into on August 1, 2022 (Filed With SEC on November 8, 2022)

Second Amendment to the Loan and Security Agreement, dated September 17, 2021, by and among Hercules Capital and the Registrant (Filed With SEC on November 8, 2022)

Form of Restricted Stock Grant Notice and Restricted Stock Agreement under Phathom Pharmaceuticals, Inc. 2019 Equity Incentive Plan (Filed With SEC on August 2, 2022)

Revenue Interest Financing Agreement, dated May 3, 2022, by and among NovaQuest Capital Management, Sagard Holding Manager, Hercules Capital and the Registrant (Filed With SEC on August 2, 2022)

Amendment to the Loan and Security Agreement, dated September 17, 2021, by and among Hercules Capital and the Registrant (Filed With SEC on August 2, 2022)

Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on August 2, 2022)

Transition and Separation Agreement and Release of Claims, dated April 5, 2022, by and between the Registrant and Anthony Guzzo (Filed With SEC on August 2, 2022)

Employment Letter Agreement, dated March 22, 2022, by and between Molly Henderson and the Company (Filed With SEC on May 10, 2022)

Description of Registered Securities (Filed With SEC on March 1, 2022)

First Amendment to the Supply and Packaging Services Agreement, by and between Sandoz GmbH and the Registrant, dated December 4, 2021 (Filed With SEC on March 1, 2022)

Form of Restricted Stock Unit Agreement under the 2019 Incentive Award Plan (Filed With SEC on January 25, 2022)

Loan and Security Agreement, dated September 17, 2021, by and among Hercules Capital and the Registrant (Filed With SEC on November 8, 2021)

Warrant to purchase stock issued to Hercules Capital, dated September 17, 2021 (Filed With SEC on November 8, 2021)

SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on August 10, 2021)

Third Amendment to the Loan and Security Agreement, dated May 26, 2021, by and among Silicon Valley Bank, SVB Innovation Credit Fund VIII, L.P. and the Registrant (Filed With SEC on August 10, 2021)

Separation and Release Agreement dated June 4, 2021, between the Registrant and Todd Branning (Filed With SEC on August 10, 2021)

Commercial Supply Agreement with Catalent Pharma Solutions, LLC entered into on July 2, 2021 (Filed With SEC on August 10, 2021)

Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on August 10, 2021)

Second Amendment to the Loan and Security Agreement, dated March 11, 2021, by and among Silicon Valley Bank, SVB Innovation Credit Fund VIII, L.P. and the Registrant (Filed With SEC on May 11, 2021)

Description of Registered Securities (Filed With SEC on March 30, 2021)

Amendment No. 1 to Takeda License Agreement, dated September 21, 2020 (Filed With SEC on March 30, 2021)

Supply and Packaging Services Agreement, by and between Sandoz GmbH and the Registrant, dated December 30, 2020 (Filed With SEC on March 30, 2021)

Amendment No. 1 to Commercial Supply Agreement by and between Takeda Pharmaceuticals Company Limited and the Registrant, dated as of December 1, 2020 (Filed With SEC on March 30, 2021)

Underwriting Agreement, dated December 16, 2020, by and among Phathom Pharmaceuticals, Inc. and Jefferies LLC, Evercore Group L.L.C., Guggenheim Securities, LLC and BMO Capital... (Filed With SEC on December 17, 2020)

Amendment No. 1 to Takeda License Agreement, dated September 21, 2020 (Filed With SEC on November 10, 2020)

Commercial Supply Agreement, by and between Takeda Pharmaceuticals Company Limited and the Company, dated as of April 30, 2020 (Filed With SEC on August 6, 2020)

Form of Stock Option Grant Notice and Stock Option Agreement under the Phathom Pharmaceuticals, Inc. 2019 Incentive Award Plan (Filed With SEC on August 6, 2020)

Form of Performance Share Unit Grant Notice and Performance Share Unit Agreement under Phathom Pharmaceuticals, Inc. 2019 Incentive Award Plan (Filed With SEC on August 6, 2020)

Employment Letter Agreement, dated June 25, 2020, by and between Todd Branning and the Company (Filed With SEC on July 13, 2020)

Phathom Pharmaceuticals 2020 Bonus Plan (Filed With SEC on May 12, 2020)

Amendment to the Loan and Security Agreement, dated March 11, 2020, by and among Silicon Valley Bank, WestRiver Innovation Lending Fund VIII, L.P. and the Registrant (Filed With SEC on May 12, 2020)

Description of Registered Securities (Filed With SEC on March 19, 2020)

Form of Underwriting Agreement (Filed With SEC on October 15, 2019)

Specimen stock certificate evidencing the shares of common stock (Filed With SEC on October 15, 2019)

Note Purchase Agreement, dated May 7, 2019, by and among the Registrant and the other parties party thereto, as amended (Filed With SEC on October 15, 2019)

Phathom Pharmaceuticals, Inc. 2019 Incentive Award Plan and form of stock option grant notice and stock option agreement thereunder (Filed With SEC on October 15, 2019)

Phathom Pharmaceuticals, Inc. 2019 Employee Stock Purchase Plan (Filed With SEC on October 15, 2019)

Non-Employee Director Compensation Program (Filed With SEC on October 15, 2019)

Form of Stock Option Grant Notice and Stock Option Agreement under Phathom Pharmaceuticals, Inc. 2019 Equity Incentive Plan (Filed With SEC on September 30, 2019)

Form of Restricted Stock Grant Notice and Restricted Stock Agreement under Phathom Pharmaceuticals, Inc. 2019 Equity Incentive Plan (Filed With SEC on September 30, 2019)

Phathom Pharmaceuticals, Inc. 2019 Incentive Award Plan and form of stock option grant notice and stock option agreement thereunder (Filed With SEC on September 30, 2019)

Phathom Pharmaceuticals, Inc. 2019 Employee Stock Purchase Plan (Filed With SEC on September 30, 2019)

Non-Employee Director Compensation Program (Filed With SEC on September 30, 2019)

Letter Agreement, dated May 7, 2019, by and between Tadataka Yamada, M.D. and the Registrant (Filed With SEC on September 30, 2019)

Employment Letter Agreement, dated July 21, 2019, by and between David Socks and the Registrant (Filed With SEC on September 30, 2019)

Amended and Restated Employment Letter Agreement, dated September 25, 2019, by and between Azmi Nabulsi, M.D., M.P.H. and the Registrant (Filed With SEC on September 30, 2019)

Employment Letter Agreement, dated July 23, 2019, by and between Aditya Kohli, Ph.D. and the Registrant (Filed With SEC on September 30, 2019)

Form of Indemnification Agreement for Directors and Officers (Filed With SEC on September 30, 2019)

License Agreement, dated May 7, 2019, by and between Takeda Pharmaceutical Company Limited and the Registrant (Filed With SEC on September 30, 2019)

Loan and Security Agreement, dated May 14, 2019, by and among Silicon Valley Bank, WestRiver Innovation Lending Fund VIII, L.P. and the Registrant (Filed With SEC on September 30, 2019)

Employment Letter Agreement, dated August 29, 2019, by and between Terrie Curran and the Registrant (Filed With SEC on September 30, 2019)

Agreement of Merger, dated March 13, 2019, by and between YamadaCo IIA, Inc. and the Registrant (Filed With SEC on September 30, 2019)

Warrant to purchase shares of common stock issued to Takeda Pharmaceutical Company Limited, dated May 7, 2019 (Filed With SEC on September 30, 2019)

Warrant to purchase stock issued to Silicon Valley Bank, dated May 14, 2019 (Filed With SEC on September 30, 2019)

Warrant to purchase stock issued to WestRiver Innovation Lending Fund VIII, L.P., dated May 14, 2019 (Filed With SEC on September 30, 2019)

Note Purchase Agreement, dated May 7, 2019, by and among the Registrant and the other parties party thereto, as amended (Filed With SEC on September 30, 2019)

Phathom Pharmaceuticals, Inc. 2019 Equity Incentive Plan (Filed With SEC on September 30, 2019)

Category

Industry

Companies

Contracts

Phathom Pharmaceuticals, Inc. Contracts & Agreements